Related Experiment Videos
A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents
J J Salata1, N K Jurkiewicz, J Wang
1Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. joseph_salata@merck.com
Molecular Pharmacology
|July 11, 1998
Summary
A novel benzodiazepine, R-L3, activates the cardiac potassium current IKs, shortening action potentials independently of beta-adrenergic stimulation. This stereospecific activation offers new insights into cardiac repolarization modulation.
Area of Science:
- Cardiology
- Molecular Pharmacology
- Ion Channel Physiology
Background:
- The slowly activating delayed rectifier K+ current (IKs) is crucial for cardiac action potential repolarization.
- Modulation of IKs impacts cardiac rhythm and electrical stability.
Purpose of the Study:
- To investigate the effects of a novel benzodiazepine derivative, R-L3, on IKs.
- To determine the mechanism and stereospecificity of R-L3's action on cardiac ion channels.
Main Methods:
- Electrophysiological recordings in guinea pig cardiac myocytes.
- Heterologous expression of KvLQT1 and hminK channels in Xenopus oocytes.
- Stereospecific evaluation using R-L3 and its enantiomer S-L3.
Main Results:
- R-L3 activated IKs and shortened action potentials, an effect independent of beta-adrenergic stimulation.
- Activation by R-L3 was stereospecific; S-L3 blocked IKs.
- R-L3 shifted the voltage dependence of IKs activation and slowed deactivation.
- R-L3 affected homomeric KvLQT1 channels but not heteromeric KvLQT1/hminK channels.
Conclusions:
- R-L3 is a novel, stereospecific activator of IKs.
- The KvLQT1/hminK interaction likely hinders R-L3 binding or efficacy.
- Findings suggest R-L3 as a potential therapeutic agent for modulating cardiac repolarization.